Most Read Articles
Smriti Rana, one year ago
Prolonged breastfeeding has a beneficial long term effect on a person’s intelligence quotient (IQ) in adulthood and may be associated with higher levels of education and income potential, a recent study has shown.
Radha Chitale, 3 years ago

Just two of the recommended three doses of human papillomavirus virus (HPV) vaccine may be enough to reduce the risk of condyloma (genital warts) infections and potentially the risk of cervical cancer, a Swedish study has shown.

8 months ago
Dr Helen Chen, head and senior consultant of the Department of Psychological Medicine at KK Women’s and Children’s Hospital (KKH) in Singapore talks about factors affecting PND and how clinicians can help their patients cope with this condition.
2 years ago
Anogenital warts, a common sexually transmitted disease, can be effectively cleared with topical nitric oxide delivered using acidified nitrate, according to a multinational group of researchers

Original New Drug Application Approvals by US FDA (1 - 15 May 2017)

2 months ago
New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

STERITALC
  • Active Ingredient(s): TALC
  • Strength: 2MG, 3MG, 4MG
  • Dosage Form: Topical Powder
  • Company: Novatech SA
  • Approval Date: May 1, 2017
  • Chemical Type: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated:
    • To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.
    • In adults to decrease the recurrence of pneumothorax
  • Approved Label: 05/01/2017 (PDF)

IMFINZI
  • Active Ingredient(s): DURVALUMAB
  • Strength: 50MG/ML
  • Dosage Form: Injectable; Injection
  • Company: Astrazeneca UK Ltd
  • Approval Date: May 1, 2017
  • Chemical Type: Not available
  • Indication(s): Indicated for the treatment of patients with:
    • Locally advanced or metastatic urothelial carcinoma who:
      • have disease progression during or following platinum-containing chemotherapy
      • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
  • Approved Label: 05/01/2017 (PDF)

KISQALI; FEMARA
  • Active Ingredient(s): LETROZOLE;RIBOCICLIB
  • Strength: 200MG
  • Dosage Form: Oral Tablet
  • Company: Novartis Pharms Corp
  • Approval Date: May 4, 2017
  • Chemical Type: Type 4 - New Combination
  • Indication(s): Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
  • Approved Label: 05/04/2017 (PDF)

RADICAVA
  • Active Ingredient(s): EDARAVONE
  • Strength: 30MG/100ML
  • Dosage Form: Injectable; Injection
  • Company: Mitsubishi Tanabe Pharma Development America Inc
  • Approval Date: May 5, 2017
  • Chemical Type: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of amyotrophic lateral sclerosis (ALS)
  • Approved Label: 05/05/2017 (PDF)

MINOLIRA
  • Active Ingredient(s): MINOCYCLINE HYDROCHLORIDE
  • Strength: 105MG, 135MG
  • Dosage Form: Extended release oral tablet
  • Company: Dr Reddys Labs Ltd
  • Approval Date: May 8, 2017
  • Chemical Type: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older
  • Approved Label: 05/05/2017 (PDF)

BAVENCIO
  • Active Ingredient(s): AVELUMAB
  • Strength: 20MG/ML
  • Dosage Form: Injectable; Intravenoues
  • Company: EMD Serono Inc
  • Approval Date: May 9, 2017
  • Chemical Type: Not available
  • Indication(s): Indicated for the treatment of:
    • Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)
    • Patients with locally advanced or metastatic urothelial carcinoma (UC) who:
      • Have disease progression during or following platinum-containing chemotherapy
      • Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
  • Approved Label: 05/09/2017 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Smriti Rana, one year ago
Prolonged breastfeeding has a beneficial long term effect on a person’s intelligence quotient (IQ) in adulthood and may be associated with higher levels of education and income potential, a recent study has shown.
Radha Chitale, 3 years ago

Just two of the recommended three doses of human papillomavirus virus (HPV) vaccine may be enough to reduce the risk of condyloma (genital warts) infections and potentially the risk of cervical cancer, a Swedish study has shown.

8 months ago
Dr Helen Chen, head and senior consultant of the Department of Psychological Medicine at KK Women’s and Children’s Hospital (KKH) in Singapore talks about factors affecting PND and how clinicians can help their patients cope with this condition.
2 years ago
Anogenital warts, a common sexually transmitted disease, can be effectively cleared with topical nitric oxide delivered using acidified nitrate, according to a multinational group of researchers